Michael Yee, global head of biotech research at UBS, joins CNBC’s ‘Squawk on the Street’ to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more. Read Full Article → Source: https://www.youtube.com/watch?v=3PnmzsrmQdk Post navigation Survey: 67% of Gen Z Are Confident in AI Returns Versus Only 50% of Boomers. Here Are 2 AI Stocks to Buy Now and Hold for Decades.
By Hidden Values Daily 